Screener
Inhibrx Biosciences, Inc. INBX Other Receivables
Other Receivables at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | MARCH 31, 2026 | DECEMBER 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $161,657 | $124,220 |
| Other receivables | 186 | 177 |
| Prepaid expenses and other current assets | 9,498 | 8,435 |
| Total current assets | 171,341 | 132,832 |
| Property and equipment, net | 3,196 | 3,733 |
| Operating right-of-use asset | 5,052 | 5,535 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s other receivables?
- Inhibrx Biosciences, Inc. (INBX) reported other receivables of $186K in Q1 2026.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s other receivables?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s other receivables has grown at a -46.0% compound annual growth rate (CAGR), from $607K to $177K.
- What does other receivables mean?
- This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.
Ask your AI about Inhibrx Biosciences, Inc.'s other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude